Skip to main content

Table 3 Description of the patients fulfilling only ACR criteria or only AECG criteria

From: Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies

Patient

Sex

Age (years)

Duration (years)a

Eyeb

Mouthc

Arthritisd

Lunge

Neurof

Parotidg

UWSFh

Schirmeri

OSSj

Chisholmk

ANA

Anti-SSAl

Anti-SSBl

RF (n < 0.2)

ACPA (n < 20)

IgG (mg/l)

Clinicalm

Detailed characteristics of the eight patients fulfilling only ACR criteria

1

F

25

0

1

0

0

0

0

0

0.35

8

3

1

160

146

46

0.14

9

9.2

SS

2

F

63

1

1

1

0

0

0

0

0.4

30

3

4

1,280

0

0

0

0

5.8

SS

3

F

34

1

1

0

1

0

0

0

0.2

20

4

4

1,280

174

0

0.5

250

16.2

RA

4

F

59

5

0

1

0

0

0

1

0.4

10

1

3

640

140

80

0.9

7

13.4

SS

5

F

61

5

1

1

0

0

0

0

0.5

8

3

3

0

0

0

0

0

12.1

Sicca

6

F

47

4

1

1

0

0

0

0

0.2

30

3

3

1,280

0

0

0

0

16.5

UCTD

7

F

57

1

1

1

1

0

1

0

0.5

30

4

4

160

0

0

0.52

250

12.7

RA

8

F

27

6

0

1

0

1

0

0

0.25

30

0

3

1,280

100

0

0.81

15

18.9

SLE

Detailed characteristics of the 15 patients fulfilling only AECG criteria

1

F

67

1

1

1

0

0

0

0

0.005

5

2

3

160

0

0

0

0

11.7

SS

2

F

45

1

1

1

0

0

0

0

0.001

5

2

2

640

154

0

0.05

0

13

SS

3

F

75

0

1

1

0

0

0

0

0.2

0

2

3

0

0

0

0.34

0

9.3

SS

4

F

56

1

1

1

0

0

0

0

0.005

25

2

2

1,280

24

152

0

0

9.9

SS

5

F

50

13

1

1

0

0

1

1

0.1

20

0

4

160

0

0

0

0

9.1

SS

6

F

69

6

1

1

0

0

0

0

0.25

5

1

4

1,280

0

0

0

0

10.3

SS

7

F

66

1

1

1

1

0

0

0

0.486

5

2

3

320

0

0

0

0

7

SS

8

F

55

7

1

1

0

1

0

0

0.02

15

2

4

160

0

0

0

0

7.1

SS

9

F

43

3

1

1

0

0

0

0

0.15

5

1

1

640

85

0

0

0

12.6

SS

10

F

78

10

1

1

0

0

0

0

0.05

7

2

3

160

0

0

0

0

9.7

SS

11

M

64

2

1

1

0

1

0

0

0.2

0

0

4

320

0

0

0

28

22.6

SS

12

F

60

8

1

1

0

0

1

1

0.05

5

2

3

640

9

32

0

72

8.43

SS

13

F

58

2

1

1

0

0

0

0

0.04

4

0

3

0

0

0

0

0

8.33

SS

14

F

43

10

0

1

0

0

0

0

0.06

0

1

2

320

40

0

0

0

10

SS

15

F

50

1

1

1

0

0

0

0

0.05

15

1

3

0

0

0

0

0

9.7

SS

  1. ACPA, anti-citrullinated peptide antibodies; ACR, American College of Rheumatology; AECG, American–European Consensus Group; ANA, antinuclear antibody; F, female; IgG, serum level of immunoglobulin G; M, male; OSS, ocular staining score; SS, Sjögren’s syndrome. RA, rheumatoid arthritis; RF, rheumatoid factor; sicca, idiopathic sicca syndrome; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue disease; UWSF, unstimulated whole salivary flow. aDuration of the symptoms. bXerophthalmia (0, absent; 1, present). cXerostomia (0, absent; 1, present). dPresence of swollen and tender joints on the day of examination. eIncludes the presence of chronic dry cough or computed tomography-proven interstitial lung disease. fPatient with objective peripheral neuropathy. gPresence or history of parotidomegaly. hAbnormal if ≤0.1 ml/minute. iSchirmer’s test abnormal if ≤ 5 mm/5 minutes. jAbnormal if ≥ 3. kChisholm’s grading of the lymphocytic infiltration on minor salivary gland biopsy (grades 3 and 4 correspond to a focus score ≥1 focus of more than 50 lymphocytes/4 mm2). lAnti-SSA and anti-SSB antibodies (n < 40). mDiagnosis made by the physician, without reference to specific classification criteria.